EFFECT OF SINGLE‐AGENT IBRUTINIB ON TUMOR DEBULKING AND REDUCTIONS IN TUMOR LYSIS SYNDROME (TLS) RISK IN PATIENTS (PTS) WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL). (June 2017) - Tam, C.S.; Byrd, J.C.; O'Brien, S.; Coutre, S.; Barr, P.M.; Furman, R.R.; Kipps, T.J.; Burger, J.A.; Stevens, D.; Sharman, J.; Ghia, P.; Flinn, I.; et al.